Stephen V Liu, MD· @StephenVLiu · X·· 3 days agoScore45
Body · original
#ESMO26 Dr. @peters_solange presents phase 3 study of sigvotatug vedotin (SV, integrin beta-6 ADC) vs docetaxel in previously treated non-squamous NSCLC. No difference in survival. Some signal in driver-negative NSCLC in 2L setting (vs 3L). #ESMOAmbassadors
64 views · 3 likes · 2 reposts · 1 reply
Replies in this thread
- Jose Fernando Moura, PhD@FernandoOnco
@StephenVLiu @peters_solange @myESMO The signs is so thin like a jamon slice
Source: Stephen V Liu, MD · x.com